Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events
Abstract Ductal carcinoma in situ (DCIS) incidence has risen rapidly with the introduction of screening mammography, yet it is unclear who benefits from both the amount and type of adjuvant treatment (radiation therapy, endocrine therapy) versus what constitutes over-treatment. Our goal was to ident...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | npj Breast Cancer |
| Online Access: | https://doi.org/10.1038/s41523-025-00774-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849769221922226176 |
|---|---|
| author | Thomas J. O’Keefe Christina Yau Emma Iaconetti Eliza Jeong Case Brabham Paul Kim Joseph McGuire Ann Griffin Anne M. Wallace Laura J. Esserman Olivier Harismendy Gillian L. Hirst |
| author_facet | Thomas J. O’Keefe Christina Yau Emma Iaconetti Eliza Jeong Case Brabham Paul Kim Joseph McGuire Ann Griffin Anne M. Wallace Laura J. Esserman Olivier Harismendy Gillian L. Hirst |
| author_sort | Thomas J. O’Keefe |
| collection | DOAJ |
| description | Abstract Ductal carcinoma in situ (DCIS) incidence has risen rapidly with the introduction of screening mammography, yet it is unclear who benefits from both the amount and type of adjuvant treatment (radiation therapy, endocrine therapy) versus what constitutes over-treatment. Our goal was to identify the effects of adjuvant radiation therapy, or endocrine ± radiation therapy versus breast conservation surgery alone in a large multi-center registry of retrospective DCIS cases (N = 1916) with median follow up of 7.0 (IQR: 8.43) years. We show that patients with DCIS who took less than 2 years of adjuvant endocrine therapy alone have a similar second event rate as breast conservation surgery. However, patients who took more than 2 years of endocrine therapy show a significantly reduced second event rate, similar to those who received either radiation or combined endocrine + radiation therapy, which was independent of age, tumor size, grade, or period of diagnosis. This highlights the importance of endocrine therapy duration for risk reduction. |
| format | Article |
| id | doaj-art-b603fa0bbdb84291b0e006689df37c6a |
| institution | DOAJ |
| issn | 2374-4677 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Breast Cancer |
| spelling | doaj-art-b603fa0bbdb84291b0e006689df37c6a2025-08-20T03:03:29ZengNature Portfolionpj Breast Cancer2374-46772025-07-011111910.1038/s41523-025-00774-3Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second eventsThomas J. O’Keefe0Christina Yau1Emma Iaconetti2Eliza Jeong3Case Brabham4Paul Kim5Joseph McGuire6Ann Griffin7Anne M. Wallace8Laura J. Esserman9Olivier Harismendy10Gillian L. Hirst11Department of Surgery, University of CaliforniaDepartment of Surgery, University of CaliforniaDepartment of Surgery, University of CaliforniaMoores Cancer Center, Division of Biomedical Informatics, UCSD School of Medicine University of CaliforniaDepartment of Surgery, University of CaliforniaDepartment of Surgery, University of CaliforniaUCSF Helen Diller Family Comprehensive Cancer CenterUCSF Helen Diller Family Comprehensive Cancer CenterDepartment of Surgery, University of CaliforniaDepartment of Surgery, University of CaliforniaMoores Cancer Center, Division of Biomedical Informatics, UCSD School of Medicine University of CaliforniaDepartment of Surgery, University of CaliforniaAbstract Ductal carcinoma in situ (DCIS) incidence has risen rapidly with the introduction of screening mammography, yet it is unclear who benefits from both the amount and type of adjuvant treatment (radiation therapy, endocrine therapy) versus what constitutes over-treatment. Our goal was to identify the effects of adjuvant radiation therapy, or endocrine ± radiation therapy versus breast conservation surgery alone in a large multi-center registry of retrospective DCIS cases (N = 1916) with median follow up of 7.0 (IQR: 8.43) years. We show that patients with DCIS who took less than 2 years of adjuvant endocrine therapy alone have a similar second event rate as breast conservation surgery. However, patients who took more than 2 years of endocrine therapy show a significantly reduced second event rate, similar to those who received either radiation or combined endocrine + radiation therapy, which was independent of age, tumor size, grade, or period of diagnosis. This highlights the importance of endocrine therapy duration for risk reduction.https://doi.org/10.1038/s41523-025-00774-3 |
| spellingShingle | Thomas J. O’Keefe Christina Yau Emma Iaconetti Eliza Jeong Case Brabham Paul Kim Joseph McGuire Ann Griffin Anne M. Wallace Laura J. Esserman Olivier Harismendy Gillian L. Hirst Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events npj Breast Cancer |
| title | Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events |
| title_full | Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events |
| title_fullStr | Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events |
| title_full_unstemmed | Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events |
| title_short | Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events |
| title_sort | insights from a multi institutional registry show duration of endocrine treatment for dcis impacts second events |
| url | https://doi.org/10.1038/s41523-025-00774-3 |
| work_keys_str_mv | AT thomasjokeefe insightsfromamultiinstitutionalregistryshowdurationofendocrinetreatmentfordcisimpactssecondevents AT christinayau insightsfromamultiinstitutionalregistryshowdurationofendocrinetreatmentfordcisimpactssecondevents AT emmaiaconetti insightsfromamultiinstitutionalregistryshowdurationofendocrinetreatmentfordcisimpactssecondevents AT elizajeong insightsfromamultiinstitutionalregistryshowdurationofendocrinetreatmentfordcisimpactssecondevents AT casebrabham insightsfromamultiinstitutionalregistryshowdurationofendocrinetreatmentfordcisimpactssecondevents AT paulkim insightsfromamultiinstitutionalregistryshowdurationofendocrinetreatmentfordcisimpactssecondevents AT josephmcguire insightsfromamultiinstitutionalregistryshowdurationofendocrinetreatmentfordcisimpactssecondevents AT anngriffin insightsfromamultiinstitutionalregistryshowdurationofendocrinetreatmentfordcisimpactssecondevents AT annemwallace insightsfromamultiinstitutionalregistryshowdurationofendocrinetreatmentfordcisimpactssecondevents AT laurajesserman insightsfromamultiinstitutionalregistryshowdurationofendocrinetreatmentfordcisimpactssecondevents AT olivierharismendy insightsfromamultiinstitutionalregistryshowdurationofendocrinetreatmentfordcisimpactssecondevents AT gillianlhirst insightsfromamultiinstitutionalregistryshowdurationofendocrinetreatmentfordcisimpactssecondevents |